Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity

Journal of Analytical Toxicology

Volumn 29, Issue 2, 2005, Pages 140-144

  Kamijo, Yoshito ^a   Hayashi, Izumi ^a   Nishikawa, Takashi ^b   Yoshimura, Kuniko ^a   Soma, Kazui ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ETHYL LOFLAZEPATE;

AGED; ARTICLE; ASPHYXIA; BODY MASS; CASE REPORT; DEATH; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MASS SPECTROMETRY; PROTEIN DETERMINATION; RECEPTOR BINDING;

EID: 15244346479     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/29.2.140     Document Type: Article

References (21)

1. B.B. Ba, A. Iliadis, A. Durand, Y. Berger, and J.P. Cano. New approach in bioavailability study of two formulation of ethyl loflazepate. Arzneim-Forsch. 38: 1486-1489 (1988).
2. K. Aizawa, M. Shibayama, A. Koutani, I. Komiya, F. Kai, M. Nishio, M. Ito, K. Kajii, and H. Yamamoto. Absorption, metabolism and excretion of ethyl loflazepate (CM 6912) in man. Jpn. Pharmacol. Ther. 14: 535-548 (1986).
3. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. N. Engl. J. Med. 288: 277-280 (1973).
4. C.M. Castleden, C.F. George, D. Marcer, and C. Hallett. Increased sensitivity to nitrazepam in old age. Br. Med. J. 1: 10-12 (1977).
5. D.J. Greenblatt, M.D. Allen, and R.I. Shader. Toxicity of high-dose flurazepam in the elderly. Clin. Pharmacol. Ther. 21: 355-360 (1977).
6. M. Schafer, J.P. Jantzen, and T. Wallenfang. Risks of premedication with benzodiazepines exemplified by a case of asphyxia caused by flunitrazepam. Anasth. Intensivther. Notfallmed. 23: 183-186 (1988).
7. R.O. Dantas and M.A. Nobre Souza. Dysphagia induced by chronic ingestion of benzodiazepine. Am. J. Gastroenterol. 92: 1194-1196 (1997).
8. W. Cautreels and J.P. Jeanniot. Quantitative analysis of CM6912 (ethyl loflazepate) and its metabolites in plasma and urine by chemical ionization gas chromatography mass spectrometry. Application to pharmacokinetics studies in man. Biomed. Mass. Spectrom. 7: 565-571 (1980).
9. T. Nishikawa, A. Nishida, H. Ohtani, W. Sunaoshi, H. Miura, Y. Sudo, and H. Kubo. Radioreceptor assay of clonazepam and diazepam in blood for therapeutic drug monitoring. Ther. Drug Monit. 11: 483-486 (1989).
10. T. Nishikawa, S. Suzuki, H. Ohtani, N.W. Eizawa, T. Sugiyama, T. Kawaguchi, and S. Miura. Benzodiazepine concentrations in sera determined by radioreceptor assay for therapeutic-dose recipients. Am. J. Clin. Pathol. 102: 605-610 (1994).
11. T. Nishikawa, Y. Kamijo, H. Ohtani, and A.D. Fraser. Oxaprozin interference with urinary benzodiazepine immunoassays and non-interference with receptor assay. J. Anal. Toxicol. 23: 125-126 (1999).
12. D.J. Greenblatt, D.R. Abernethy, A. Locniskar, J.S. Harmatz, R.A. Limjuco, and R.I. Shader. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61: 27-35 (1984).
13. R.K. Roberts, G.R. Wilkinson, R.A. Branch, and S. Shenker. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479-485 (1978).
14. A.F. Macklon, M. Barton, O. James, and M.D. Rawlins. The effect of age on the pharmacokinetics of diazepam. Clin. Sci. 59: 479-483 (1980).
15. J. Kanto, M. Maenpaa, R. Mantyla, R. Sellman, and E. Valovirta. Effect of age on the pharmacokinetics of diazepam given in conjunction with spinal anesthesia. Anesthesiology 51: 154-159 (1979).
16. D.R. Abernethy, D.J. Greenblatt, M. Divoll, and R.I. Shader. Prolonged accumulation of diazepam in obesity. J. Clin. Pharmacol. 23: 369-376 (1983).
17. D.R. Abernethy, D.J. Greenblatt, M. Divoll, R.B. Smith, and R.I. Shader. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin. Pharmacokinet. 9: 177-183 (1984).
18. L.P. Novak. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J. Gerontol. 27: 438-443 (1972).
19. D.J. Greenblatt and C.E. Wright. Clinical pharmacokinetics of alprazolam. Therapeutic implication. Clin. Pharmacokinet. 24: 453-471 (1993).
20. M.K. Grandison and F.D. Boudinot. Age-related changes in protein binding of drugs: implications for therapy. Clin. Pharmacokinet. 38: 271-290 (2000).
21. C.G. Swift, J.M. Ewen, P. Clarke, and I.H. Stevenson. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br. J. Clin. Pharmacol. 20: 111-118 (1985).